Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that clinical and preclinical results from studies of all three of its investigational drugs -- AndexXa™ (andexanet alfa), betrixaban and cerdulatinib -- will be presented at the upcoming 58 th American Society of Hematology (ASH) Annual Meeting and Exposition, which is taking place from December 3-6 at the San Diego Convention Center.

AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Betrixaban, which has Fast Track designation from the FDA, is an oral Factor Xa inhibitor anticoagulant in development for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Cerdulatinib, an oral, dual Syk/JAK kinase inhibitor, is in development to treat patients with resistant or relapsed hematologic cancer.

The abstracts are now available at https://ash.confex.com/ash/2016/webprogram/start.html. Following are details of the oral and poster presentations, which will include additional data not available in the abstracts.

AndexXa™ (andexanet alfa)
  • Abstract Title: Reversal of betrixaban-induced anticoagulation in healthy volunteers by andexanet alfa

             Publication #: 143             Presenting Author: Mark Crowther, M.D., MSc, FRCPC, Professor, Department of Medicine, Hematology and Thromboembolism and Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario             Oral Session Name: 332. Antithrombotic Therapy: Anticoagulation and Bleeding             Presentation Date and Time: Saturday, December 3, 1:00 p.m. PT             Presentation Location: Room 30
  • Abstract Title: Andexanet alfa reverses anticoagulation effects of enoxaparin and associated bleeding in a rabbit acute hemorrhage model

If you liked this article you might like

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Norwegian Cruise Line, iRobot, Bank of America: 'Mad Money' Lightning Round

What's Getting In This Rally's Way: Cramer's 'Mad Money' Recap (Thurs 8/24/17)

These Biotech Stocks are BOOMING

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All